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Herein, we describe a case of youngwoman initially undergoing evaluation for infertility whowas found to have
malignant melanoma arising in a mature dermoid cyst. She subsequently underwent unilateral salpingo-
oophorectomy with staging procedure with benign pathology. There was no need for adjuvant therapy and
the patient is without disease to date (nearly 10-months in follow-up now).We reviewed the existing literature
and this is one of only a few cases documented in the last decade.
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Literature review1. Introduction
Although mature teratomas (MTs), also known as dermoid cysts,
compromise 10–20% of ovarian neoplasms globally (Park et al.,
2008), malignant transformation is very rare occurring in only
0.17–2% of MT cases (Hackethal et al., 2008). The most frequent ma-
lignancy arising in MTs is squamous cell carcinoma (88.3%) (Crouet
et al., 1986), followed by adenocarcinoma, ﬁbrosarcoma, carcinoid
tumor and mixed tumors. Malignant melanoma is among the least
common transformations, with estimated incidence of 0.2–0.8%
(Mandal et al., 2010).
A review of 36 cases during 1901 to 2009 has been reported by
Xu et al. (2011), showing only six patients surviving N2-years,
while only one patient had no evidence of disease (NED) 5-years
post-diagnosis. Another review by Ueng et al. (2010) discussed
four cases of this tumor type. Prognosis was poor, with all dying 3,
17, 18 and 5 months, respectively, post-diagnosis. Herein, we de-
scribe a rare case of this tumor type and discuss various options for
management/treatment.gic Oncology, Florida Hospital
FL 32804, USA.
e), sarfraz.ahmad@ﬂhosp.org
. This is an open access article under2. Case presentation
A 35-year-old Hispanic female, G0, referred by her Reproductive En-
docrinologist. While undergoing evaluation for infertility, pelvic ul-
trasound demonstrated a pelvic mass versus ﬁbroid measuring
6.2 × 6.6 cm, midline to the left. The left ovary contained multiple
follicles measuring 3.4 × 1.8 cm, and a dominant follicle measuring
2.4 × 1.8 cm. There was a contiguous mass, which measured
8.2 × 6.3 × 7.4 cm, present anteriorly, abutting the uterus and left
ovary. The lesion was suggestive of a large hemorrhagic cyst or an
endometrioma. She complained of pain in left lower quadrant that
was crampy in nature.
The patient underwent surgical assessment in conjunction with Re-
productive Endocrinology. Diagnostic hysteroscopy followed by lapa-
roscopy was performed revealing a 10 cm mass apparently originating
from right ovary and two pedunculated uterine ﬁbroids, which mea-
sured ~2 cm and ~5 mm, respectively. Given the size of ovarian mass,
the procedurewas converted to laparotomy and the ovarywas exterior-
ized. The right ovary was exteriorized from the abdominal cavity.
During cystectomy, the cyst ruptured without evidence of intra-
abdominal spillage. A myomectomy was also performed. Pathology
revealed a unilocular cyst ﬁlled with sebaceous material and hair. A
1-cm Rokitansky nodule was present but no other nodules or
papillations were identiﬁed. Microscopic examination of the ovarian
cyst revealed a mature cystic teratoma containing 7 mm focus of mela-
noma, which was predominantly intra-epidermal; but contained a fewthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Nests of melanoma in situ are present at the epithelial-stromal junction and
invasive melanoma is present in the stroma accompanied by a prominent lymphocytic
reaction (H&E, 20×).
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with a dense lymphocytic inﬁltrate (Figs. 1–3). No lymphatic invasion
was identiﬁed and the melanoma did not involve surface of the ovary.
Histologic sections were reviewed at Johns Hopkins Pathology Depart-
ment with diagnostic concurrence.
For further assessment, CT scan was performed post-operatively.
This showed a complex left ovarian cyst with a thickened wall, measur-
ing 2.3 cm and a simple-appearing right ovarian cyst measuring 3.1 cm,
and showed no evidence of retroperitoneal lymphadenopathy. PET scan
was also obtained which showed no evidence of metastasis. The case
was reviewed at our multi-disciplinary tumor board. Given the patho-
logical ﬁndings of the malignant melanoma on initial surgery, recom-
mendation was to perform right salpingo-oophorectomy and a staging
procedure.
The patient then underwent robotic-assisted laparoscopic right
salpingo-oophorectomy, right pelvic and aortic lymphadenectomy,
omental biopsy, intra-peritoneal biopsies and left ovarian cystectomy.
All pathologywas benign. The right tube and ovary showed no evidence
of residual melanoma.
Post-operatively, the patient did well and is without disease to date
(nearly 10-months in follow-up now). The case was again discussed at
tumor board and no further treatment was recommended, other than
close surveillance.
3. Discussion
Mature cystic teratomas (MCTs) constitute 10–20% of all ovarian
neoplasms. They tend to present in young women, around the age of
30-years. MCTs are composed of well-differentiated derivations from
at least two of the three germ cell layers (i.e., ectoderm, mesoderm,
and endoderm). They contain developmentally mature skin complete
with hair follicles and sweat glands, sometimes luxuriant clumps of
long hair and pockets of sebum, blood, fat, bone, nails, teeth, eyes, carti-
lage and thyroid tissue. MTs are usually benign, but undergo malignant
transformation in b0.2% of cases, and reported incidence of 1–3%byRim
et al. (2006). Several malignancies may develop from any of the three
germ-cell layers, such as adenocarcinoma, malignant thyroid struma,
carcinoid tumors, melanomas and a variety of soft tissue sarcomasFig. 1. Mature squamous epithelium in the ovarian teratoma contains numerous
junctional nests of atypical melanocytes. Arrows mark an area shown at higher power
(H&E stain, 4×).(Rim et al., 2006). The most common malignant evolution is squamous
cell carcinoma (SCC) from ectoderm (Rim et al., 2006). Malignant mel-
anoma arising within MCT is extremely rare, with an estimated inci-
dence of b1%.
We reviewed nine recent cases of malignant melanoma arising in a
mature cystic teratoma reported during 2011–2015 (Table 1). The
ages of the patients ranged 24–75 years, with an average of 51.1 years.
Initial diagnosiswas anovarianmass inmost cases. Four of ninepatients
had evidence of metastatic disease. The standard treatment for these
patients was surgery, speciﬁcally unilateral salpingo-oophorectomy
(USO) or total abdominal hysterectomy with bilateral salpingo-
oophorectomy+/− staging procedure. Six of nine patients received ad-
juvant chemotherapy, while three patients additionally received immu-
notherapy. Like our case, two received no adjuvant therapy. Four
patients had distant metastases, all of whom died of disease (DOD) at
the time of publication. Out of ﬁve patients without metastasis, two
were reported with NED and the follow-up for the other two was
unknown (Table 1). From this, we can conclude distant metastasis
plays a signiﬁcant role in prognosis in a tumor of this type. Therefore,
evaluation of the patient for metastases is of paramount importance,
and either surgical staging or PET imaging should be considered in
these patients. The possibility of a melanoma arising at another site,
such as skin, central nervous system, eye and gastrointestinal tract
with secondary involvement of the ovary tract, needs to be excluded.Fig. 3. Invasive melanoma (H&E, 40×).
Table 1
Demographics and patient characteristics of malignant melanoma arising in a mature cystic teratoma reported in the peer-reviewed literature during the years 2011 to 2015.
Authors Year Age
(years)
Initial diagnosis Tumor
size (cm)
Procedures performed Surgical
staging
Adjuvant therapy Distant
Mets
Prognosis
Lee, et al. 2011 71 Pelvic cystic mass 15 × 12 ×
11
BSO, total hysterectomy, Oment,
left adrenalectomy, and Append
Yes Chemotherapy
(cisplatin-dacarbazine-vincristine)
Yes Died 5
months
after initial
diagnosis
Menci 2011 24 Right ovarian mass 15 × 9 × 8 RSO, sampling of right and left
pelvic gutters, pelvic lymph
nodes, bowel adhesions, bladder
serosa, omentum
Yes Chemotherapy, immunotherapy
(interferon), taxol
Yes Died 7
months
after initial
diagnosis
Xu, et al. 2011 33 Right ovarian
cystic mass
8 × 7 × 5 Right ovarian cystectomy,
hysterectomy, BSO
No Chemotherapy (dacarbazine),
immunotherapy (interferon)
No NED at 26
months
Godoy, et al. 2012 64 Right-sided
pleural effusion,
an ovarian mass,
ascites
Un-known Laparotomy, hysterectomy, BSO,
omentectomy, resection of diffuse
tumoral implants
No Chemotherapy (temozolamide) No Unknown
Hyun & Mun 2013 75 Pelvic mass 20 × 14 LTH, BSO, partial Oment,
cholecystectomy
No Chemotherapy, immunotherapy
(interferon)
Yes Died 17
months
after initial
diagnosis
Lee, et al. 2014 38 Left adnexal mass 12 × 13 Left salpingo-oophorectomy No None No Unknown
Genc, et al. 2015 54 Right ovarian cyst 14 TAH, left salpingo-oophorectomy,
PAL, appendectomy, Oment
Yes Immunotherapy (interferon),
radiotherapy
Yes NED at 12
months
post-surgery
Black, et al. 2015 45 – 20 TAH, BSO, PAL, Oment Yes None Yes Died 18
months
post-surgery
Kudva, et al. 2015 56 Right ovarian mass 20 × 13 ×
16
TAH, BSO, pelvic lymph node
sampling, infra-colic
omentectomy, Append
Yes Chemotherapy No NED at last
follow-up
Current case
(Brudie, et al.)
2016 35 Left ovarian mass 10 RAL, right
salpingo-oophorectomy, right
PAL, left ovarian cystectomy
Yes None No NED at
10-months
Abbreviations: BSO = bilateral salpingo-oophorectomy, RSO = right salpingo-oophorectomy, NED = no evidence of disease, TAH = total abdominal hysterectomy, PAL = pelvic-and-
aortic lymphadenectomy, LTH = laparoscopic total hysterectomy, RAL = robotic-assisted laparoscopy, Oment = omentectomy, Append = appendectomy, Mets = metastasis.
49L.A. Brudie et al. / Gynecologic Oncology Reports 16 (2016) 47–50In our patient's tumor, melanoma in situ was present in the terato-
ma, thereby conﬁrming its origin, but post-operatively she also
underwent dermatologic exam, and radiologic imaging with CT follow-
ed by PET to assess for distant metastasis. These were negative for me-
tastasis. She ultimately had USO of the affected ovary with surgical
staging which showed no residual melanoma. She is currently with
NED, 14 months from time of surgical staging.
Pre-operative detection of malignant transformation of a MCT is dif-
ﬁcult, thereby increasing the likelihood of tumor spread while reducing
patient survival. When comparing data of MCT cases with those of ma-
lignant transformation, malignancy usually occurs in middle-aged
women and the tumor diameter tends to be larger withmalignant com-
ponents, compared to tumors of pure benign nature. Gynecologic exam-
ination with pelvic ultrasound should be performed in women with a
pelvic mass, as 80% of mature cystic teratomas are diagnosed during
the reproductive age (Rim et al., 2006).
Due to the rarity of malignant melanoma within MT, there is a
paucity of information in the literature regarding treatment or prog-
nosis but multiple drugs have been shown to be efﬁcacious. Multiple
chemotherapy regimens have been offered in recent years to these pa-
tients. In recent reports, patients received chemotherapy consisting of
dacarbazine, cisplatin and taxol. Extrapolating from treatment of cuta-
neous melanoma, immunotherapy alone or in combination with che-
motherapy has also proven effective.
There may also be consideration of molecular/biological approaches
in treatment of malignant melanoma. For example, BRAF is a serine/
threonine protein kinase activating theMAP kinase/ERK-signaling path-
way, and its mutations are seen in about 50% of melanomas (over 90%
V600E). Compared to chemotherapy, BRAF inhibition targeted therapy
has shown clinical beneﬁts including progression-free survival, overall
survival and objective response rate in patients with malignantmelanoma, unrelated to the gynecologic tract. A recent study has
shown BRAF inhibitor (dabrafenib), in combination with MEK inhibitor
(trametinib), enhance tumor growth inhibition, delay acquired resis-
tance and eliminate paradoxical activation of the MAPK pathway in
pre-clinical models of melanoma. In addition, the combination of MEK
inhibitors to the therapy removes the adverse effects of BRAF inhibitors
alone, which include patient relapse around 7-months after targeted
therapy and development of secondary cutaneous SCC and hyperkera-
totic lesions within the ﬁrst 2–3 months of therapy, seen in 14–26% of
patients with metastatic melanoma.
Malignant transformations of MTs, especially those of malignant
melanomas, are difﬁcult to diagnose and treat. Based on the litera-
ture, prognosis of malignant melanomas arising in a mature terato-
ma is poor, with an overall 5-year mortality rate of 90%, although
data is limited. Our review of recent reported cases shows different
approaches including a combination of surgery, chemotherapy and/
or immunotherapy (Table 1). Patient outcome is unpredictable
even when favorable treatments are used. With more cases arising,
establishing a successful therapy and improving mortality rate is be-
coming more likely.
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